4.2 Article

Treatment with Anti-Interleukin 23 Antibody Ameliorates Disease in Lupus-Prone Mice

Journal

BIOMED RESEARCH INTERNATIONAL
Volume 2013, Issue -, Pages -

Publisher

HINDAWI LTD
DOI: 10.1155/2013/861028

Keywords

-

Funding

  1. National Institutes of Health [K23 AR055672, R01 AR060849, RO1 AI085567]

Ask authors/readers for more resources

Interleukin 23 receptor expressing IL-17 producing T cells have been shown to be important in the development of murine lupus. The usefulness of IL-23 inhibition in ameliorating lupus nephritis is unknown. We hypothesized that inhibition of IL-23 will ameliorate nephritis in lupus-prone mice. To this end, we treated MRL/lpr lupus-prone mice for 6 weeks with a rat anti-IL-23p19 antibody, which resulted in delaying the onset of nephritis without affecting the production of anti-dsDNA antibodies. The effect of the treatment was hampered by the production of murine anti-rat IgG antibodies. The amelioration of murine lupus by IL-23 inhibition strengthens the rationale for targeting IL-23 in patients with systemic lupus erythematosus.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available